Cardior Pharmaceuticals

We are proud to have been represented at the Falling Walls Foundation Science Summit 2024, where our CEO & Co-Founder, Dr. Claudia Ulbrich moderated the panel session “Biomedical Innovation Ecosystems: Recipes for Success.” The session brought together leading experts to discuss how collaboration, cutting-edge research, and strategic investment are driving breakthroughs in healthcare and improving patient outcomes. Thank you to the Falling Walls Foundation for hosting such an inspiring event to advance the future of biomedical innovation.

We’re pleased to announce that Dr. Claudia Ulbrich, will be attending the 34th Frankfurt European Banking Congress, hosted by Germany’s leading banks in Frankfurt am Main. This year’s theme, “Out of the Comfort Zone: Europe and the New World Order,” promises insightful discussions with influential leaders from the political, business, financial, and academic sectors on Europe’s evolving role in the global landscape. We’re eager to explore how these insights connect to the biotech sector and impact financial markets. If you’re attending, be sure to connect with Claudia during the conference! #EuropeanBankingCongress #Biotech #Finance

Our CEO and Co-Founder, Dr. Claudia Ulbrich, is joining a panel discussion at the HQ Trust Investors Forum 2024 during Euro Finance Week. Claudia will speak alongside financial experts from investment firms and academia and share her experience from Cardior’s recent acquisition by Novo Nordisk, providing insights into our journey from early innovation to strategic growth. Learn more about the conference here: https://lnkd.in/ed2Hwrsh #EuroFinanceWeek #HQTrustForum #BiotechInnovation

We are happy to share that Cardior Pharmaceuticals’ CEO and Co-Founder Dr. Claudia Ulbrich is going to attend Jefferies 2024 London Healthcare Conference held in London on November 19-21.  The conference provides a comprehensive overview of the global healthcare sector and highlights upcoming trends. If you are attending as well, make sure to get in touch! 

Later this week, CEO and Co-Founder Dr. Claudia Ulbrich Ulbrich and CSO/CMO and Founder Dr. Thomas Thum will participate in the 2024 Falling Walls Science Summit, where thought leaders in science, business, and policy unite to explore innovative solutions and break down barriers in science. November 8: Claudia will join the Executive Table discussion on Charting a Path towards Precision Heart Health. This exclusive session brings together global experts to address the urgent challenges in heart health, exploring transformative research, AI applications, and personalized medicine. November 9: Both Claudia and Thomas will participate in the Executive Table discussion on Engineering Biology. This conversation will delve into how harnessing biological systems can reshape healthcare by accelerating vaccine development, diagnostics, and biologics production for a more accessible and robust global health landscape. Claudia Ulbrich will moderate the Roundtable Discussion on Biomedical Innovation Ecosystems: Recipes for Success. This session will explore the critical components of a thriving biomedicine innovation ecosystem, from funding and regulatory support to tech advancements and knowledge-sharing culture. #FallingWalls #ScienceSummit #Innovation

We are very excited that Cardior Pharmaceuticals’ CEO and Co-Founder Dr. Claudia Ulbrich is invited to speak at BioMed Life Science Day organized by BioMed Partners in Basel, Switzerland on October 31, 2024. Claudia will recount her experiences from founding a start-up to the acquisition by Novo Nordisk, as well as share the challenges faced and the lessons learned.

Cardior Pharmaceuticals’ founder and CSO/CMO, the Head of Institute for Molecular and Translational Therapeutic Strategies (#IMTTS) of Hannover Medical School (#MHH) Professor Thomas Thum will take part in the DIA/FDA Oligonucleotide-Based Therapeutics Conference in Washington, DC this week and speak on Cardiac Delivery of Nucleotides on Monday 28 October at 11:00 ET. #Oligo24  

Cardior Pharmaceuticals’ CEO and Co-Founder Dr. Claudia Ulbrich is in Oslo this week to take part in Hadean Annual Event 2024 organized by #Hadeanventures held in the world famous #Munchmuseeum on October 23-24. In her company presentation Claudia will speak on the latest developments at Cardior as well as share her own experiences during this exciting journey from the inception of the company to its acquisition by Novo Nordisk, one of the most notable #lifescience deals in 2024. 

We want to congratulate the 2024 Nobel Prize winners for their remarkable discovery of microRNAs as key regulatory elements in the genome. This milestone has reshaped our understanding of gene regulation and its role in health and disease.   At Cardior, which was acquired by Novo Nordisk earlier in 2024, we are proud to be leading the world’s largest study on microRNA therapeutics in cardiovascular patients. The Nobel Prize-winning discovery of microRNAs forms the foundation of our pioneering work, as we leverage the knowledge to develop therapies that transform cardiovascular care and bring hope to patients in an area with significant unmet needs.   #Cardior #NovoNordisk #miRNA #DrivingChange #NobelPrize2024 #InnovativeMedicine #ScientificBreakthroughs

Join Dr. Sandor Batkai, M.D., Ph.D. , Cardior Pharmaceuticals’ Co-founder & Head of Medical Research and Intelligence, at the 3rd Annual Heart Failure Drug Discovery & Development Summit in Boston, MA.  The forum focuses entirely on preclinical research in #heartfailure drug development. On Thursday, August 1 Sandor is holding the presentation “Delving into Non-Coding RNA Pathways in Addressing Cardiac Diseases”. Check the agenda for details and stop by: https://lnkd.in/dMxPwGmR